Biotech Values

[drbio45]

>Any comments on how SNY's Multaq, which was approved today for AF, stacks up against ARYX's AF compound?<

Multaq was in a trial with patients with heart failure, more people died on the drug than the placebo.

they next trial SNY did excluded heart failure patients so it met the endpoint.

this mean that Multaq will not be used in patients with hf, or at least shouldn't be used. I believe that is 60 percent of the market.

Aryx's drug had good data and I think 60 percent of the patients in the trial had hf. Not only that they asked the patients in the trial how they felt and the heart failure patient were able to breathe better on the drug.

I think it will be differentiated